These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 21935931

  • 1. Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
    Yang KT, Wang MC, Chen JY, Hsu MC, Hung WC.
    J Cell Physiol; 2011 Nov; 226(11):2849-56. PubMed ID: 21935931
    [Abstract] [Full Text] [Related]

  • 2. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
    Hsu MC, Chang HC, Hung WC.
    Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
    [Abstract] [Full Text] [Related]

  • 3. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
    Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD.
    J Biol Chem; 2000 Dec 15; 275(50):39223-30. PubMed ID: 11010972
    [Abstract] [Full Text] [Related]

  • 4. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC, Zhao C, Yang ZD, Zhang XL, Wu WR, Pan J, Zhao C, Li ZQ, Ding W, Yang Z, Si WK.
    Int J Mol Med; 2013 Feb 15; 31(2):453-8. PubMed ID: 23233089
    [Abstract] [Full Text] [Related]

  • 5. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
    Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N.
    Blood; 2005 Jan 15; 105(2):775-83. PubMed ID: 15353483
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL, Corrêa S, Salles D, Du Rocher B, Santiago MF, Abdelhay E.
    BMC Cancer; 2014 Nov 23; 14():866. PubMed ID: 25417721
    [Abstract] [Full Text] [Related]

  • 7. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE.
    Clin Cancer Res; 2000 May 23; 6(5):1958-68. PubMed ID: 10815921
    [Abstract] [Full Text] [Related]

  • 8. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E, Vidovic K, Lassen C, Richter J, Olofsson T, Fioretos T, Gullberg U.
    Leukemia; 2007 Dec 23; 21(12):2485-94. PubMed ID: 17728783
    [Abstract] [Full Text] [Related]

  • 9. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C.
    EMBO J; 2007 Mar 07; 26(5):1456-66. PubMed ID: 17318191
    [Abstract] [Full Text] [Related]

  • 10. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
    Huang Q, Yang Y, Li X, Huang S.
    Tumour Biol; 2011 Dec 07; 32(6):1191-7. PubMed ID: 21892628
    [Abstract] [Full Text] [Related]

  • 11. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, Yu L.
    Oncogene; 2014 Jan 02; 33(1):44-54. PubMed ID: 23208504
    [Abstract] [Full Text] [Related]

  • 12. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
    Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR.
    Blood; 2011 Sep 08; 118(10):2840-8. PubMed ID: 21715304
    [Abstract] [Full Text] [Related]

  • 13. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 14. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
    Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S, Liu Q, Tauchi T, Miyazawa K, Endo H, Nagai T, Ozawa K.
    J Biol Chem; 2003 Feb 21; 278(8):6411-9. PubMed ID: 12456669
    [Abstract] [Full Text] [Related]

  • 15. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
    Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M, Warmuth M.
    Blood; 2003 Jan 15; 101(2):655-63. PubMed ID: 12393654
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.
    Cancer Res; 2005 Apr 15; 65(8):3264-72. PubMed ID: 15833859
    [Abstract] [Full Text] [Related]

  • 18. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T.
    Oncogene; 2002 Aug 29; 21(38):5868-76. PubMed ID: 12185586
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.
    Cancer Res; 2009 Dec 15; 69(24):9337-45. PubMed ID: 19934315
    [Abstract] [Full Text] [Related]

  • 20. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 15; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.